o(6)-benzylguanine has been researched along with Astrocytoma, Grade IV in 17 studies
O(6)-benzylguanine: a suicide inhibitor of O(6)-methylguanine-DNA methyltransferase activity
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 9.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumors including malignant glioblastoma." | 7.76 | Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. ( Jin, YH; Liu, HY; Shu, F; Wang, QJ; Wang, Z; Yang, Y; Zhang, WB, 2010) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 7.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells." | 7.73 | Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. ( Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R, 2006) |
| "Temozolomide (TMZ) is one of the most potent chemotherapy agents for the treatment of glioblastoma." | 5.19 | Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. ( Adair, JE; Baldock, AL; Beard, BC; Born, DE; Bridge, CA; Gonzalez-Cuyar, LF; Gori, JL; Guyman, LA; Hawkins-Daarud, A; Johnston, SK; Kiem, HP; Mrugala, MM; Rockhill, JK; Rockne, RC; Silbergeld, DL; Storer, BE; Swanson, KR, 2014) |
| "This phase II trial was designed to define the efficacy of Gliadel wafers in combination with an infusion of O6-benzylguanine (O6-BG) that suppresses tumor O6-alkylguanine-DNA alkyltransferase (AGT) levels in patients with recurrent glioblastoma multiforme for 5 days and to evaluate the safety of this combination therapy." | 5.14 | Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. ( Bigner, DD; Carter, J; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Jiang, SX; McLendon, RE; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Threatt, S; Vredenburgh, JJ, 2009) |
| "Resistance to temozolomide (TMZ) based chemotherapy in glioblastoma multiforme (GBM) has been attributed to the upregulation of the DNA repair protein O(6)-methylguanine-DNA methyltransferase (MGMT)." | 3.80 | Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors. ( Chiarelli, PA; Ellenbogen, RG; Fang, C; Hatzinger, SJ; Kievit, FM; Silber, JR; Stephen, ZR; Veiseh, O; Wang, K; Zhang, M, 2014) |
| "Methylating drugs such as temozolomide (TMZ) are widely used in the treatment of brain tumors including malignant glioblastoma." | 3.76 | Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition. ( Jin, YH; Liu, HY; Shu, F; Wang, QJ; Wang, Z; Yang, Y; Zhang, WB, 2010) |
| "The DNA repair and detoxifying enzymes, O(6)-methylguanine-DNA-methyltransferase (MGMT) and glutathione-S-transferase (GST), may be responsible fpr poor response to alkylating agents in glioblastoma treatment." | 3.74 | Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase. ( Benhattar, J; Bernasconi, CC; Bricod, C; Gros, S; Janzer, RC; Juillerat-Jeanneret, L; Trepey, S, 2008) |
| "In this study, we investigated the mechanisms by which temozolomide enhances radiation response in glioblastoma cells." | 3.73 | Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. ( Aldape, K; Black, PM; Chakravarti, A; Erkkinen, MG; Gilbert, MR; Loeffler, JS; Mehta, M; Nestler, U; Stupp, R, 2006) |
| "This study was designed to determine whether resistance to the activity of nitrosourea (the drug BCNU) in BCNU-resistant human medulloblastoma (D341 Med) and human glioblastoma multiforme (D-456 MG) can be reversed by the methylating agent streptozocin and the O6-substituted guanines O6-methylguanine and O6-benzylguanine." | 3.68 | Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. ( Bigner, DD; Dolan, ME; Felker, GM; Friedman, HS; Moschel, RC; Pegg, AE; Rich, J; Schold, SC, 1992) |
| "Twenty-three patients were treated (22 with glioblastoma multiforme and one with anaplastic astrocytoma)." | 2.69 | Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. ( Ashley, DM; Bigner, DD; Cokgor, I; Colvin, OM; Dolan, ME; Ewesuedo, RB; Friedman, AH; Friedman, HS; Garcia-Turner, AM; Haglund, MM; Herndon, JE; Long, L; McLendon, RE; Moschel, RC; Pegg, AE; Pluda, J; Provenzale, JM; Quinn, JA; Rich, JN; Sampson, J; Stewart, ES; Tourt-Uhlig, S, 2000) |
| " When this regimen was administered to mice containing humanized bone marrow, flow cytometric analyses indicated that the human bone marrow cells were significantly more sensitive to treatment than the murine bone marrow cells and that the regimen was highly toxic to human-derived hematopoietic cells of all lineages (progenitor, lymphoid, and myeloid)." | 1.37 | Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. ( Bailey, B; Baluyut, AR; Cai, S; Chan, RJ; Ernstberger, A; Goebel, WS; Jones, DR; Juliar, BE; Mayo, LD; Pollok, KE; Sinn, AL; Wang, H, 2011) |
| " The solubility, metabolism, bioavailability and effectiveness of O6-benzylguanine as an adjuvant therapy with BCNU were compared using two vehicles, cremophor-EL and PEG 400." | 1.29 | Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL. ( Dolan, ME; Flora, KP; Friedman, HS; Grever, MR; Moschel, RC; Pegg, AE; Vishnuvajjala, BR, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (35.29) | 18.2507 |
| 2000's | 5 (29.41) | 29.6817 |
| 2010's | 5 (29.41) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Das, A | 1 |
| Henderson, FC | 1 |
| Alshareef, M | 1 |
| Porto, GBF | 1 |
| Kanginakudru, I | 1 |
| Infinger, LK | 1 |
| Vandergrift, WA | 1 |
| Lindhorst, SM | 1 |
| Varma, AK | 1 |
| Patel, SJ | 1 |
| Cachia, D | 1 |
| Qian, L | 1 |
| Zheng, J | 1 |
| Wang, K | 2 |
| Tang, Y | 1 |
| Zhang, X | 1 |
| Zhang, H | 1 |
| Huang, F | 1 |
| Pei, Y | 1 |
| Jiang, Y | 1 |
| Adair, JE | 1 |
| Johnston, SK | 1 |
| Mrugala, MM | 1 |
| Beard, BC | 1 |
| Guyman, LA | 1 |
| Baldock, AL | 1 |
| Bridge, CA | 1 |
| Hawkins-Daarud, A | 1 |
| Gori, JL | 1 |
| Born, DE | 1 |
| Gonzalez-Cuyar, LF | 1 |
| Silbergeld, DL | 1 |
| Rockne, RC | 1 |
| Storer, BE | 1 |
| Rockhill, JK | 1 |
| Swanson, KR | 1 |
| Kiem, HP | 1 |
| Stephen, ZR | 1 |
| Kievit, FM | 1 |
| Veiseh, O | 1 |
| Chiarelli, PA | 1 |
| Fang, C | 1 |
| Hatzinger, SJ | 1 |
| Ellenbogen, RG | 1 |
| Silber, JR | 1 |
| Zhang, M | 1 |
| Juillerat-Jeanneret, L | 1 |
| Bernasconi, CC | 1 |
| Bricod, C | 1 |
| Gros, S | 1 |
| Trepey, S | 1 |
| Benhattar, J | 1 |
| Janzer, RC | 1 |
| Quinn, JA | 2 |
| Jiang, SX | 1 |
| Carter, J | 1 |
| Reardon, DA | 1 |
| Desjardins, A | 1 |
| Vredenburgh, JJ | 1 |
| Rich, JN | 2 |
| Gururangan, S | 1 |
| Friedman, AH | 3 |
| Bigner, DD | 5 |
| Sampson, JH | 1 |
| McLendon, RE | 4 |
| Herndon, JE | 3 |
| Threatt, S | 1 |
| Friedman, HS | 6 |
| Zhang, WB | 1 |
| Wang, Z | 1 |
| Shu, F | 1 |
| Jin, YH | 1 |
| Liu, HY | 1 |
| Wang, QJ | 1 |
| Yang, Y | 1 |
| Cai, S | 1 |
| Wang, H | 1 |
| Bailey, B | 1 |
| Ernstberger, A | 1 |
| Juliar, BE | 1 |
| Sinn, AL | 1 |
| Chan, RJ | 1 |
| Jones, DR | 1 |
| Mayo, LD | 1 |
| Baluyut, AR | 1 |
| Goebel, WS | 1 |
| Pollok, KE | 1 |
| Chakravarti, A | 1 |
| Erkkinen, MG | 1 |
| Nestler, U | 1 |
| Stupp, R | 1 |
| Mehta, M | 1 |
| Aldape, K | 1 |
| Gilbert, MR | 1 |
| Black, PM | 1 |
| Loeffler, JS | 1 |
| Koch, D | 1 |
| Hundsberger, T | 1 |
| Boor, S | 1 |
| Kaina, B | 1 |
| Marathi, UK | 1 |
| Dolan, ME | 6 |
| Erickson, LC | 1 |
| Pegg, AE | 5 |
| Moschel, RC | 5 |
| Vishnuvajjala, BR | 1 |
| Flora, KP | 1 |
| Grever, MR | 1 |
| Wedge, SR | 1 |
| Newlands, ES | 1 |
| Kurpad, SN | 1 |
| Archer, GE | 1 |
| Kokkinakis, DM | 1 |
| Pluda, J | 2 |
| Cokgor, I | 2 |
| Haglund, MM | 2 |
| Ashley, DM | 2 |
| Rich, J | 2 |
| Kerby, T | 1 |
| Schold, SC | 2 |
| Ewesuedo, RB | 1 |
| Long, L | 1 |
| Colvin, OM | 1 |
| Sampson, J | 1 |
| Provenzale, JM | 1 |
| Stewart, ES | 1 |
| Tourt-Uhlig, S | 1 |
| Garcia-Turner, AM | 1 |
| Felker, GM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Benzylguanine-Mediated Tumor Sensitization With Chemoprotected Autologous Stem Cells for Patients With Malignant Gliomas[NCT00669669] | Phase 1/Phase 2 | 12 participants (Actual) | Interventional | 2009-02-25 | Terminated (stopped due to Terminated due to loss in funding.) | ||
| Phase II Trial of Gliadel Plus 06-Benzylguanine for Patients With Recurrent Glioblastoma Multiforme[NCT00362921] | Phase 2 | 52 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024] | Phase 2 | 50 participants (Anticipated) | Interventional | 2015-03-31 | Active, not recruiting | ||
| A Pilot Study Investigating Neoadjuvant Temozolomide-based Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas[NCT00881595] | Phase 2 | 0 participants (Actual) | Interventional | 2009-02-28 | Withdrawn (stopped due to No patients accrued since study opened) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
From the onset of temozolomide to the date at which unequivocal disease progression, assessed up to 65 months. (NCT00669669)
Timeframe: Up to 65 months
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4.5 |
Assessed by gene marking in peripheral blood prior to chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.78 |
Assessed by gene marking in peripheral blood after chemoselection. Gene marking is assessed in whole blood by quantitative PCR and reported as a vector copy number (VCN) or the average copies of integrated transgene per cell. The units here will be reported as copies/cell. (NCT00669669)
Timeframe: Up to 59 months
| Intervention | copies/cell (Mean) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0.50 |
Defined as any grade 4 nonhematopoietic toxicity that is likely related to the investigational procedures (Part I) (NCT00669669)
Timeframe: Up to 6 weeks after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment until death, assessed up to 74 months. (NCT00669669)
Timeframe: Up to 74 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
assessed by the ability to increase the Temozolomide dose beyond 472 mg/m^2 (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 2 |
assessed by the increase in peripheral blood Vector Copy Number (VCN), the average copies of integrated transgene per cell, after chemotherapy (NCT00669669)
Timeframe: Up to 59 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 4 |
Replication competent retrovirus or diagnosis of leukemia (NCT00669669)
Timeframe: Up to 2 years after infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 0 |
Number of patients with reduction in tumor burden of a predefined amount (NCT00669669)
Timeframe: Up to 66 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 1 |
From the first day of treatment (transplant) until unequivocal progression is documented, assessed up to 66 months. (NCT00669669)
Timeframe: Up to 66 months.
| Intervention | months (Median) |
|---|---|
| Treatment (Chemotherapy, Autologous Stem Cell Transplant) | 5.5 |
4 trials available for o(6)-benzylguanine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients.
Topics: Adult; Bone Marrow; Brain Neoplasms; Carmustine; Combined Modality Therapy; Dacarbazine; DNA Modific | 2014 |
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Decanoic A | 2009 |
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma.
Topics: Adult; Aged; Brain Neoplasms; Enzyme Inhibitors; Glioblastoma; Guanine; Humans; Middle Aged; O(6)-Me | 1998 |
Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Carmustine; Central Nervous Syst | 2000 |
13 other studies available for o(6)-benzylguanine and Astrocytoma, Grade IV
| Article | Year |
|---|---|
MGMT-inhibitor in combination with TGF-βRI inhibitor or CDK 4/6 inhibitor increases temozolomide sensitivity in temozolomide-resistant glioblastoma cells.
Topics: Aminopyridines; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; A | 2021 |
Cationic core-shell nanoparticles with carmustine contained within O⁶-benzylguanine shell for glioma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cations; | 2013 |
Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors.
Topics: Animals; Brain Neoplasms; Glioblastoma; Guanine; Magnetic Resonance Imaging; Magnetics; Mice; Mice, | 2014 |
Heterogeneity of human glioblastoma: glutathione-S-transferase and methylguanine-methyltransferase.
Topics: Alkylating Agents; Brain Neoplasms; Carmustine; Cell Line, Tumor; Cell Proliferation; DNA Methylatio | 2008 |
Activation of AMP-activated protein kinase by temozolomide contributes to apoptosis in glioblastoma cells via p53 activation and mTORC1 inhibition.
Topics: AMP-Activated Protein Kinases; Antineoplastic Agents, Alkylating; Apoptosis; bcl-2-Associated X Prot | 2010 |
Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Cells; Cell Line, | 2011 |
Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms.
Topics: Animals; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Dacarbazine; Disease Models, Animal | 2006 |
Local intracerebral administration of O(6)-benzylguanine combined with systemic chemotherapy with temozolomide of a patient suffering from a recurrent glioblastoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2007 |
Anti-neoplastic activity of sequenced administration of O6-benzylguanine, streptozotocin, and 1,3-bis(2-chloroethyl)-1-nitrosourea in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Glioblastoma; Guanine; Humans; | 1994 |
Biodistribution of O6-benzylguanine and its effectiveness against human brain tumor xenografts when given in polyethylene glycol or cremophor-EL.
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Agents; Carmustine; Child; Chromatography, High Pre | 1994 |
O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.
Topics: Animals; Antineoplastic Agents; Astrocytoma; Body Weight; Carmustine; Cell Division; Cell Line; Daca | 1996 |
Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3-bis(2-chloroethyl)-1-nitrosourea.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine | 1997 |
Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme.
Topics: Animals; Carmustine; Drug Resistance; Female; Glioblastoma; Guanine; Humans; Male; Medulloblastoma; | 1992 |